Wang, MengzhaoMengzhaoWangCHIH-HSIN YANGMitchell, Paul LPaul LMitchellFang, JianJianFangCamidge, D RossD RossCamidgeNian, WeiqiWeiqiNianChiu, Chao-HuaChao-HuaChiuZhou, JianyingJianyingZhouZhao, YanqiuYanqiuZhaoSu, Wu-ChouWu-ChouSuYang, Tsung-YingTsung-YingYangZhu, Viola WViola WZhuMillward, MichaelMichaelMillwardFan Y.Huang, Wen-TsungWen-TsungHuangCheng, YingYingChengJiang, LiyanLiyanJiangBrungs, DanielDanielBrungsBazhenova, LyudmilaLyudmilaBazhenovaLee, Chee KhoonChee KhoonLeeGao, BoBoGaoXu, YanYanXuHsu, Wei-HsunWei-HsunHsuZheng, LiLiZhengJänne, Pasi APasi AJänne2023-03-022023-03-022022-07-062159-8274https://scholars.lib.ntu.edu.tw/handle/123456789/628828Epidermal growth factor receptor exon 20 insertion mutations (EGFRexon20ins) are detected in approximately 2% of patients with non-small cell lung cancer (NSCLC). Due to a lack of effective therapy, the prognosis of these patients is typically poor. Sunvozertinib (DZD9008) was designed as an oral, potent, irreversible, and selective EGFR tyrosine kinase inhibitor, showing activity against EGFRexon20ins and other mutations. In both cell lines and xenograft models, sunvozertinib shows potent antitumor activity. In the two ongoing phase I clinical studies, sunvozertinib was tolerated up to 400 mg once daily. The most common drug-related adverse events included diarrhea and skin rash. Antitumor efficacy was observed at the doses of 100 mg and above in patients with EGFRexon20ins NSCLC across different subtypes, with prior amivantamab treatment as well as with baseline brain metastasis. The median duration of response has not been reached.en1ST-LINE TREATMENT; OPEN-LABEL; MOLECULAR HETEROGENEITY; AZD9291; CHEMOTHERAPY; RESISTANCE; GEFITINIBjournal article10.1158/2159-8290.CD-21-1615354043932-s2.0-85134360433WOS:000874890600001https://api.elsevier.com/content/abstract/scopus_id/85134360433